MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics, Inc. (MYGN) reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in the year-ago quarter.Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, MYGN’s share price remained unchanged at $17.64 in ...